Aims: To describe the real-world prevalence and consequences of hypertriglyceridaemia.
| INTRODUCTION
Residual cardiovascular (CV) risk in statin-treated patients persists despite control of LDL cholesterol. 1 Other atherogenic lipids and lipoproteins, such as triglycerides (TGs) and TG-rich lipoproteins (TRLs), are also likely causal and prognostic factors as well as potential treatment targets in atherosclerotic CV disease (ASCVD). 1, 2 The biological plausibility of elevated TG and TRL levels as factors in residual CV risk is supported by epidemiological, genetic and clinical evidence. TG levels correlate with heightened risk for CV events in patients with well-controlled LDL cholesterol levels on statin therapy. 3 Given that
TGs are hydrophobic and do not float freely in plasma but are carried in such TG-enriched lipoproteins as VLDL, VLDL remnants and intermediate-density lipoprotein (IDL), the relationships observed probably reflect atherogenic effects exerted by both TGs and TRLs; this is reflected in non-HDL cholesterol. [4] [5] [6] [7] [8] [9] [10] [11] TG-enriched remnants, which include both small VLDL and IDL, are proinflammatory, induce endothelial dysfunction, and can be isolated from atheromatous plaque. 5, 11 In addition to the direct association between TG levels and CVD risk, elevated TGs also contribute to the atherogenic lipid triad. In patients with elevated TGs, there is typically a reduction in the activity of lipoprotein lipase, the enzyme primarily responsible for hydrolysing Epidemiological studies have shown that elevated TGs correlate with elevated CV risk, [12] [13] [14] and the American Heart Association (AHA) has long recognized that elevated TGs are a marker of CV risk. 15 The role of elevated TGs in the development and progression of ASCVD has been further elucidated in genetic studies, [16] [17] [18] [19] [20] [21] [22] [23] genome-wide analysis studies, [24] [25] [26] [27] and Mendelian randomization studies. 14, [28] [29] [30] [31] Some common polymorphisms have been associated with higher TG levels and increased CV risk, including APOA5 and LPL variants. 32 Analyses of clinical data have also demonstrated that lower on-treatment TGs correlate with reduced CV risk. 3, 33 TRLs can modulate ASCVD by becoming trapped in the subendothelial space, where they are scavenged by macrophages to form foam cells, which potentiate both inflammation and atherosclerotic plaque formation. 34 There is evidence that fatty acids produced from TGs and
TRLs are pro-inflammatory and contribute to atherogenesis. [35] [36] [37] Inflammatory mediators lead to increased expression of vascular cell adhesion molecule-1, which leads to adhesion of monocytes and T-helper cells. 38 Inflammation and increased influx of leukocytes into the intima trigger atherosclerotic changes and ultimately create the pathophysiological environment for the development of ASCVD. 34 As a result of the increasing prevalence of metabolic syndrome, diabetes and obesity, which induces the "atherogenic dyslipidaemia"
phenotype, 39, 40 41 The final sample included 9593 adults aged ≥20 years (projected to represent 219.9 million in the overall US population) who had morning fasting TG data available. A subgroup of 1448 adults also had a diagnosis of diabetes.
Based on population-weighted estimates from this analysis, 26%
of US adults (~57 million individuals) and nearly one-third of statin users have TG levels ≥1.69 mmol/L (Table 1) . 41 This is broadly in agreement with a similar analysis conducted in a European cohort in which 21% had TG levels ≥1.69 mmol/L. 42 This means that greater proportions of patients that were not treated with statins had desirable TG levels (<1.69 mmol/L) compared with statin-treated patients (Table 1) . 41 Among all adults, with or without statin treatment, there was a significant (P < 0.0001) increase in the American College of Cardiology (ACC)/AHA 10-year ASCVD risk score across increasing TG strata ( Figure 1A ). 41 It was estimated that over the next decade, 3.4 million ASCVD events will occur among people with TG levels ≥150 mg/dL, with about one-third of expected events to occur among statin users.
| Optum Research Database
The Optum Research Database is a retrospective observational administrative claims database that includes >160 million individuals and electronic health records for >80 million patients. 44 , 45 The analysis of the impact of TG on health outcomes from this database included patients with ≥1 claim for statin treatment. Figure 1B ). 45 Increased CV risk was apparent, even with addition of non-HDL cholesterol to the multivariate model and when analysing HDL cholesterol subgroups. 45 In this model, diabetes (hazard ratio [HR] 1.37, 95% CI 1.26-1.48; P < 0.001), male gender (HR 1.32, 95% CI 1.24-1.40; P < 0.001) and ASCVD (HR 2.16, 95% CI 2.01-2.33; P < 0.001) were significant predictors of major CV events. Only a minority of patients in the study had any intervention for management of elevated TGs, so there was little change in TG levels over the course of the study. The mean TG level initially decreased, then increased during the first year, before stabilizing at a concentration slightly below baseline in the TG ≥1.69 mmol/L cohort; TG levels increased in the comparison group. LDL cholesterol also did not change substantially during follow-up, despite the fact that persistence with statin therapy was poor, with~20% continuing therapy after 5 years in both the elevated-TG group and the control group. 46 After controlling for patient characteristics, there was also a higher rate of inpatient hospital stay per unit time (all P < 0.001; Table 2 , Figure 1B ). 44 , 45 The total healthcare cost ratio was higher in the TG ($2628) in the comparator cohort (P < 0.001). 44 Again, extrapolated to the overall study population over 1 year, this difference resulted in average healthcare costs that were $24 m greater in the hypertriglyceridaemia subcohort, or an additional $220 m per year per 100 000 patients compared with the comparator cohort. 44 
| Kaiser Permanente database
The Kaiser Permanente database contains electronic health records (rather than administrative claims) collected via an integrated clinical delivery system that provides medical care to patients in eight semiautonomous regions of the United States, including the Northwest (KPNW) and Southern California (KPSC) regions. 47 Both organizations use an Epic-based electronic health record (Verona, Wisconsin, USA) that is combined with enrolment, laboratory and pharmacy data to create a comprehensive dataset that can be standardized into a common data model. This longitudinal observational cohort study investigated the impact of TG levels on CVD risk using data from the KPNW and KPSC regions, which together serve~4.5 million members. The inclusion criteria for this analysis mirrored the entry criteria for the REDUCE-IT study. 48 All patients aged ≥45 years with a charted diagnosis of MI, stroke, acute coronary syndrome or peripheral arterial disease, TG levels <5.65 mmol/L and LDL cholesterol levels 1.04-2.59 mmol/L while on statin therapy were included (use of other lipid-lowering drugs was an exclusion criterion). 47 Patients were F I G U R E 1 Effect of hypertriglyceridaemia on risk, outcomes, healthcare utilization and costs. 41, 44, 45, 47, 50 A, Estimated number of atherosclerotic cardiovascular disease (ASCVD) events in 10 years among people aged 40-79 years, by triglyceride (TG) concentration, and stratified by statin use, based on the 9593 participants identified in the National Health and Nutrition Examination Survey (NHANES) database. The estimated number of events in 10 years was calculated by multiplying the estimated ASCVD risk score by the corresponding projected population (the estimated ASCVD risk score also indicated the proportion of events expected to occur in 10 years). The 10-year risk of ASCVD was defined as non-fatal myocardial infarction (MI) or coronary heart disease death, or fatal or non-fatal stroke, over a 10-year period among people free from ASCVD at the beginning of the period. followed from the index date for a maximum of 6.5 years. 47 The treatment groups differed at baseline in that the hypertriglyceridaemia group was younger, had a higher prevalence of diabetes and chronic kidney disease, and was more likely to be white or Hispanic, a current smoker, and have lower HDL cholesterol versus the TG <1.69 mmol/L group. 47 The crude prevalence of the composite outcomes did not differ between the groups at any time during the study, but crude prevalence of non-fatal MI (P = 0.023), coronary revascularization (P < 0.001) and peripheral revascularization (P = 0.026) were significantly more frequent in the hypertriglyceridaemia group versus the TG <1.69 mmol/L group. 47 There was no significant difference in the rate ratio between men and women (P = 0.698). 47 However, with multivariate statistical adjustment and accounting for time to event, the hypertriglyceridaemia group was found to be 10% more likely to experience a second primary composite outcome event versus the TG <1.69 mmol/L group (P = 0.041; Table 3 ). 47 This difference was largely driven by increased likelihoods of non-fatal MI, coronary revascularization and peripheral revascularization in the hypertriglyceridaemia group versus the TG <1.69 mmol/L group (Table 3, Figure 1C ). 47 Although rates were elevated in the hypertriglyceridaemia group versus the TG <1.69 mmol/L group, no significant differences were observed for other endpoints (ie, first composite outcome, non-fatal stroke, unstable angina, aneurysm repair, all-cause mortality; Table 3 , Figure 1C ). 47 Similar patterns were seen in an analysis of patients with diabetes and hypertriglyceridaemia (TG levels 2.26-5.64 mmol/L; n = 5542) versus normal TG levels (TG <1.69 mmol/L; n = 22 411) from this database. 49 The hypertriglyceridaemia group versus the TG <1.69 mmol/L group within the diabetes population had significantly higher adjusted incidences of non-fatal MI (rate ratio 1.30, 95% CI inpatient days (P = 0.038), emergency room visits (P < 0.001), and pharmaceutical dispenses (P < 0.001). 50 In models further adjusted for baseline costs, presence of diabetes, hypertension, chronic kidney disease, obesity and low HDL cholesterol, the following mean annualized adjusted percapita costs were significantly higher in the hypertriglyceridaemia group versus the TG <1.69 mmol/L group: total costs (by $964; P = 0.006; Table 3 , Figure 1C ), emergency room visits ($70; P = 0.031), hospital ambulatory care ($199; P = 0.032), total ambulatory care ($327; P = 0.035), and pharmaceutical dispenses ($185; P = 0.012).
| STRENGTHS AND LIMITATIONS
The populations to be statistically controlled for group differences including demographic and cardiometabolic risk factors. 44, 45, 47, 50 Because this approach was not taken for the Kaiser Permanente analysis, its ability to control for the same factors may not be as great. As a result, hypertriglyceridaemia was the main difference in risk factors between the groups, so it is likely that the observed differences in CV disease risk can be ascribed, at least in part, to the disparity in TG levels. A limitation of these analyses, however, is that it was not possible to control for other potential confounding factors such as alcohol use and other lifestyle factors that were not captured in these databases.
Data collected for the purpose of claims, or from electronic medical records of managed care health plans rather than for research, may contain inaccurate recording of health events, may have missing data, and there may be uncertainty about the internal validity of the database. 52, 53 For instance, patient fasting status cannot be accurately determined from observational laboratory data such as those used in this study, and the data probably contain a mix of fasting and non-fasting TG results.
While fasting TG values may be preferred for diagnosing hypertriglyceridaemia, 54 non-fasting TG values may be better predictors of CV disease risk. 55, 56 Non-fasting TG values are generally higher than fasting TG, 54, 57 and resulting misclassification would bias the results of this real-world analysis toward the null hypothesis, suggesting that the estimates of excess CV disease risk due to hypertriglyceridaemia may be conservative. In addition, some costs to the patient (eg, transportation, missed work days) are not available from these databases.
In addition to the limitations discussed above, a number of other issues should be kept in mind when considering these findings. Observational studies based on registries, electronic medical records, and other non-prospective real-life cohorts cannot conclusively determine causality, but are more generalizable to clinical practice than results of clinical trials. 51, 53 Biases and confounding due to unmeasured variables are possible outside the context of well-controlled randomized trials. 52 Furthermore, analyses of this type of database cannot be effectively used to determine cause and effect, that is, to measure the efficacy of pharmaceutical interventions. 51, 53 As a result, it cannot be determined from these analyses whether risk, costs and resource utilization could be reduced by TG-lowering intervention. Despite these limitations, realworld evidence provides clinicians, payers and clinical guideline developers with additional information to guide decision-making. 53 The findings of the Optum Research Database and Kaiser Permanente studies are generally consistent, with some notable differences.
With regard to age, sex and diabetes status, the Optum analyses (~85% had diabetes) may have been more similar to the Kaiser Permanente analysis of patients with diabetes than to the main Kaiser Permanente analysis, which had ≤50% patients with diabetes and the population was generally older and had more men than the Optum and Kaiser Permanente diabetes analyses. Accordingly, the rates for MI and stroke were similar between the Optum and the Kaiser Permanente diabetes analyses. 44 , 49 The Optum analysis used propensity matching whereas the Kaiser Permanente analysis used statistical controls 49 ; therefore, the Kaiser Permanente results are more subject to residual confounding. The lower admissions and costs found in the Kaiser Permanente analyses may have been attributable to the fact that the Kaiser Permanente system is a much more controlled system than the claims data used in the Optum analysis. Finally, the findings of these studies may be suggestive of elevated TG level as a greater risk factor in women than men because the Optum analysis included more women (~50%) and generally found higher risk than the Kaiser Permanente main analysis (31%-37% women).
44,50
The Results from omega-3 fatty acid outcomes trials have also had variable results. 61 Early findings conducted prior to current statin treatment guidelines that suggested possible CV benefit were either conducted with a combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 62 or with pure EPA. 63 However, later studies in the modern statin era that investigated EPA + DHA combinations failed to demonstrate CV benefit. [64] [65] [66] [67] [68] Notably, these studies had design issues such as the use of low-dose omega-3 treatment and a focus on patients with low HDL cholesterol rather than hypertriglyceridaemia. [64] [65] [66] [67] [68] Other limitations included a lack of assessment of long-chain omega-3 fatty acid status prior to and during treatment, and an absence of a clear biological target. 61 In the past year, several is forecasted that as many as 3.4 million ASCVD events will occur in this population over the next 10 years. 41 The series of real-world evidence studies reviewed here suggests that statin-treated patients with high CV risk and hypertriglyceridaemia have worse CV and health economic outcomes than similar patients with normal TG (<1.69 mmol/L in the Kaiser Permanente database), or with normal TG and HDL cholesterol (<1.69 mmol/L and >1.04 mmol/L, respectively, in the Optum database). 41, 44, 45, 47, 50 Recently completed and ongoing intervention trials designed to assess CV outcomes in patients with elevated TG levels will help to determine if certain strategies to reduce TG will help to ameliorate the residual CV risk in these patients.
